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Abstract
Background: Glioblastoma multiforme (GBM) is the most common primary central nervous system malignancy
and its unique invasiveness renders it difficult to treat. This invasive phenotype, like other cellular processes, may
be controlled in part by microRNAs - a class of small non-coding RNAs that act by altering the expression of
targeted messenger RNAs. In this report, we demonstrate a straightforward method for creating invasive
subpopulations of glioblastoma cells (IM3 cells). To understand the correlation between the expression of miRNAs
and the invasion, we fully profiled 1263 miRNAs on six different cell lines and two miRNAs, miR-143 and miR-145,
were selected for validation of their biological properties contributing to invasion. Further, we investigated an
ensemble effect of both miR-143 and miR-145 in promoting invasion.
Methods: By repeated serial invasion through Matrigel®-coated membranes, we isolated highly invasive
subpopulations of glioma cell lines. Phenotypic characterization of these cells included in vitro assays for
proliferation, attachment, and invasion. Micro-RNA expression was compared using miRCURY arrays (Exiqon). In situ
hybridization allowed visualization of the regional expression of miR-143 and miR-145 in tumor samples, and
antisense probes were used investigate in vitro phenotypic changes seen with knockdown in their expression.
Results: The phenotype we created in these selected cells proved stable over multiple passages, and their
microRNA expression profiles were measurably different. We found that two specific microRNAs expressed from the
same genetic locus, miR-143 and miR-145, were over-expressed in our invasive subpopulations. Further, we also
found that combinatorial treatment of these cells with both antisense-miRNAs (antimiR-143 and -145) will
abrogated their invasion without decreasing cell attachment or proliferation.
Conclusions: To best of our knowledge, these data demonstrate for the first time that miR-143 and miR-145
regulate the invasion of glioblastoma and that miR-143 and -145 could be potential therapeutic target for anti-
invasion therapies of glioblastoma patients.
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Background
Glioblastoma multiforme (GBM) is the most common
primary brain tumor in adults, and the discovery of this
tumor in patients portends a dismal prognosis. The
median survival of only 12-18 months is due, at least in
part, to its invasive phenotype - rendering complete sur-
gical resection nearly impossible. Even more distressing
to patients, family members, and caregivers is the loss of
neurological function that accompanies tumor invasion,
recurrence, and repeated treatments. Understanding and
controlling the invasive phenotype of glioblastoma offers
hope of improving therapies and preserving meaningful
function.
Currently, various investigators are completing, or have
recently finished, clinical trials of small molecule inhibi-
tors in glioblastoma patients based on molecular observa-
tions of protein expression and signaling cascades (e.g.
inhibitors of VEGF, TGF-beta, EGFR, m-TOR) [1].
* Correspondence: swkoo@tamu.edu; gtoussaint@medicine.tamhsc.edu
1Department of Neuroscience and Experimental Therapeutics, Texas A&M
Health Science Center College of Medicine, Bryan, TX 77843, USA
Full list of author information is available at the end of the article
Koo et al. BMC Cancer 2012, 12:143
http://www.biomedcentral.com/1471-2407/12/143
© 2012 Koo et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
A new molecular signaling paradigm has been described
in the last decade, offering more potential therapeutic
targets to alter the malignant phenotype of this disease.
MicroRNAs (miRNAs) are noncoding small RNA
molecules which regulate post-transcriptional gene
expression and have been proposed as novel cancer bio-
markers and potential targets of new anticancer therapies
[2]. Several groups have reported data describing the
microRNA expression profiles of glioblastma [3,4]. For
example, miR-124a, -125a, -29b, -7, -128 have been
reported as a glioblastma tumor suppressors while miR-
21 increases glioblastoma cell growth by targeting p53
and TGF-b [4,5]. In recent years, a handful of microRNA
species have been linked specifically to glioblastoma
brain invasion [5-7].
Herein, we describe a simple and reproducible method
for creating subpopulations of glioblastoma cells with
enhanced invasive properties. We present microRNA
expression data differentiating these invasive cells, and
provide a rationale for investigating miR-145 and mir-143
further. Finally, we confirm the expression of miR-143 and
miR-145 in invasive locations within glioblastoma samples
and, via knockdown experiments, illustrate reduced inva-
sion when their expression is abrogated.
Methods
Cell lines and culture conditions
The human glioma cell lines U87MG, U251, U373 and the
rat glioma cell line C6 were obtained from the American
Type Culture Collection (ATCC, Manassas, VA, USA).
The cells were grown in Dulbecco’s modified Eagle’s med-
ium (DMEM, Cellgro Media tech)) supplemented with
10% heat-inactivated fetal bovine serum, penicillin (10 IU/
ml), and streptomycin (10 ug/ml). The cells were main-
tained at 37°C in a humidified air atmosphere at 5% CO2.
Serial selection for a sub-population of invasive cells
using Boyden chambers
For selection of invasive cells, a suspension of 300,000
tumor cells/mL in serum-free DMEM (500 ul total
volume) was plated in the upper chamber of a Boyden-
type manifold, over a Matrigel-coated membrane (24-well
insert; pore size, 8 um; BD Biosciences). DMEM medium
containing 10% FBS in the lower chamber served as the
chemoattractant. After incubation for 21 h at 37°C, those
non-invading cells from the upper surface of the mem-
brane were scrubbed off with cotton swabs. The cells that
invaded to the bottom surface of the insert were trypsi-
nized and seeded into flasks containing DMEM supple-
mented with 10% FBS. These cells were propagated and
went through the above selection procedure twice more.
The cells that were collected after the third selection pro-
cedure were propagated resulting in the invasive sub-
population cell line termed IM3.
Boyden chamber invasion assay
For migration assays, a suspension of 300,000 tumor cells/
ml in serum-free DMEM (500 ul total volume) was plated
in the upper chamber of a Matrigel-coated membrane
insert (24-well insert; pore size, 8 um; BD Biosciences).
DMEM medium containing 10% FBS in the lower cham-
ber served as the chemoattractant. The cells were incu-
bated at 37°C for various times depending on our
laboratory experience regarding their relative speeds of
invasion (18 hrs for U87 and U251; 36 hrs for U373;
17 hrs for C6). The non-invading cells were removed with
cotton swabs. Those cells that had migrated to the lower
side of the membrane were fixed and stained with hema-
toxylin. The invading cells on quadruplicate membranes
were quantitated by counting across a diameter of each
memebrane under 40X microscopic magnification.
Cell attachment assay
For the cell attachment assay, wells of a 24-well tissue cul-
ture plate were coated with Matrigel Basement Membrane
Matrix (BD Biosciences) diluted 1:10 with serum-free
medium for 2 h at room temperature. The unbound mate-
rial was aspirated and the wells were rinsed with serum-
free medium. Cells were detached with trypsin/EDTA and
rinsed in serum free medium. Approximately 20,000 cells/
ml in 10% DMEM were plated into the wells, and the
plate was incubated at 37°C for 4 h. Wells were gently
washed with PBS and the attached cells were fixed in 4%
paraformaldehyde and stained with hematoxylin QS (Vec-
tor Laboratories) for 2 min. Wells were washed again in
PBS and the stained cells were counted.
Proliferation assay
For each cell line, parental and IM3 cells were plated at a
density of 5000 cells per well, each in 8 wells of 96-well
plates containing 10% FBS/DMEM and maintained at
37°C. The rate of cell proliferation was determined using
CellTiter 96 AQueous One Solution (Promega, Madison,
WI) at 4, 24, 48, 72 and 96 hours after plating. An MTS
assay was performed by following the protocol previously
reported [8]. Eight media only containing wells were used
to normalize the absorbance values of the wells contain-
ing cells. Growth curves were generated with normalized
absorbance compared to the 4-hour data, at 24, 36, 48,
and 72 hours.
RNA isolation
Total cellular RNA was extracted using the mirVana
miRNA Isolation kit (Ambion) per manufacturer’s
instructions for total RNA isolation. The RNA concentra-
tion was determined by spectrophotometric absorbance
at 260 nm, and the quality of the RNA was determined
by Agilent 2100 Bioanlayzer instrument (Agilent Tech-
nologies, Santa Clara, CA). All RNA samples showed
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high quality (RNA integrity number (RIN) > 9.0) and
were without RNA degradation or DNA contamination.
Real-time quantitative RT-PCR analysis
qRT-PCR was performed in triplicate by using LNA™
PCR primer sets (miR-143, -145 and U6), SYBR®Green
PCR kit, and the ViiA™ 7 real-time PCR system (Exiqon).
Total RNA extracted from U87, U251, U373, and their
corresponding invasive subpopulations, was used for
cDNA synthesis (Exiqon). The PCR reaction was started
with cDNA (140 ng/μl) in 25 μl (total) assay mix. The
PCR cycle settings were those recommended by Exiqon:
95°C, 10 min; 40 amplification cycle at 95°C (10 s) and
65°C (1 min), 1.6°C/s ramp-rate.
Knockdown miRNA transfection
Parental and IM-3 cells from each of three cell lines (U87,
U251, U373) cells were transfected with either fluorescein-
labeled locked nucleic acid (LNA) antagomirs targeting
miR-143 and miR-145 (Exiqon, Vedbaek, Denmark) at a
final concentration of 50 nM (each probe) using Lipofecta-
mine 2000 per manufacturer’s instructions (Invitrogen,
Carlsbad, CA). Control cells were transfected with an un-
targeted antagomir at a final concentration of 100 nM.
Transfection medium was changed 8 hours after transfec-
tion and replaced with Optimem medium (Invitrogen
Carlsbad, CA) for overnight recovery. The efficiency of the
transfection was assessed with fluorescence microscope.
A Double knockdown transfection of U87 and U87 IM3
cells using fluorescein-labeled miR-143 and miR-145
knockdown probe at final concentration of 50 nM each
and control LNA knockdown probe at final concentration
of 100 nM was performed using Lipofectamine 2000 per
manufacturer’s instructions. Once again, culture medium
was changed 8 hours after transfection and replaced with
Optimem medium (Invitrogen Carlsbad, CA) for overnight
recovery and the efficiency of the transfection was assessed
with fluorescence microscopy. Antisense micro RNAs
(antimir-143 and -145) for knockdown were purchased
from Exiqon.
Boyden chamber migration assay of knockdown miRNA
Transfected cells
A suspension of 300,000 cells/mL in serum-free medium
of parental and IM3 cells transfected with LNA antago-
mirs (against miR-143 and miR-145 or a control LNA
antagomir) was plated in the upper chamber of a Boyden
manifold over a Matrigel-coated membrane (24-well
insert; pore size, 8 um; BD Biosciences). DMEM medium
containing 10% FBS in the lower chamber served as the
chemoattractant. The cells were incubated for 17-36 hours
at 37°C. The non-invading cells were removed with cotton
swabs. Those cells that had migrated to the lower side of
the membrane were fixed and stained with DAPI. The
invading cells of quadruplicate membranes were counted
under the microscope at 40× magnification.
In situ detection of miRNAs
In situ detection of miRNAs was performed on 8-10-um
frozen tissue sections from xenografts of human GBM
tumors in mouse brain. Sections were fixed using fresh
ice-cold 4% paraformaldehyde for 1 h, acetylated in acetic
anhydride/triethanolamine, and prehybridized in hybridi-
zation solution (50% formamide, 5X SSC, 0.5 mg/mL yeast
tRNA, 1X Denhardt’s solution) at 25°C below the pre-
dicted Tm value of the LNA probe for 30 min. Probes
(4 pmol; fluorescein isothiocyanate (FITC)-labeled LNA-
modified oligonucleotide; Exiqon) complementary to the
mature miRNA (miR-143 and miR-145) were hybridized
to the sections for 2 h at 25°C lower than predicted Tm
value of the LNA probe. Post-hybridizations washes
were performed in 0.5X SSC at 8°C above the hybridiza-
tion temperature and the in situ hybridization signal
was detected by incubation with horseradish peroxidase
(HRP)-conjugated anti-FITC. The signal was then ampli-
fied using FITC-conjugated tyramide (Tyramide Signal
Amplification Plus Kit, Fluorescein, Perkin-Elmer) accord-
ing to the manufacturer’s instructions. Slides were
mounted in Vectashield Hard Set mounting medium con-
taining 4’,6-diamidino-2-phenylindole (DAPI) (Vectashield
mounting medium with DAPI, Vector Laboratories) and
analyzed with an Olympus CKX41 microscope equipped
with a CCD camera and Olympus software.
Statistical analysis
Data are presented as mean +/- standard deviation. For
parental and IM-3 comparisons, the Student’s t test (two-
tailed) was used to determine statistical significance. A
student’s t test with a value of P < 0.05 was considered
significant.
Results
Creation and characterization of highly invasive
glioblastoma cell line subpopulations
Serial selection for invasion through Matrigel®-coated
Boyden chamber membranes is a viable tool to separate
glioblastoma cell lines into parental and highly-invasive
sub-populations (IM3 cells). Confirmatory assays
revealed 15-, 5-, 20- and 1.5-fold (U87, U251, U373 and
C6 cells lines) increases in the number of invading cells
when comparing selected IM3 populations to their par-
ental counterparts (Figure 1B, 2A, Additional file 1A).
This phenotypic alteration has been consistent through
multiple (up to 20) passages, and at least 3 freeze-thaw
cycles. Possible confounders for Boyden chamber inva-
sion data were investigated. Enhanced attachment to
Matrigel® or an increase in cellular proliferation could
complicate the interpretation of invasion results. We
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investigated both, and found no significant differences in
these assays between parental and IM3 cell lines (Figure
2B, C, Additional file 1B). Serial selection resulted in a
stable and predictable phenotype.
Both miR-145 and miR-143 are expressed at a high level
in IM3 cell lines
Using the human miRCURY LNA microarray platform
from Exiqon, we analyzed expression of all miRBASE
v.16 human microRNAs, and compared data between
parental and IM3 cells (Figure 3). The resulting list of
preferentially expressed miRNAs was filtered in the fol-
lowing manner: 1) probeset data was collected when 6
data points were nontrivial - parental and IM3 subpopu-
lations of all 3 human lines each produced adequate
RNA hybridization for data above background, 2) the
resulting fold change data was sorted according to high-
est observed fold-change, 3) the top 38 miRNAs, all
with at least one fold change > 2, were analyzed looking
for the direction of change between parental lines and
IM-3 subpopulations to be similar between U87, U251,
and U373 data. That is, we were interested in miRNAs
that either moved uniformly up or down in invasive
subpopulations. We found that miR-143 and -145 were
over-expressed in all three IM3 cell lines compared to
their parental counterparts (Figure 3B, red arrow). The
expression level of miR-143 in IM3 cells is 2.5, 1.5 and
7.5 times higher than that of parental cells, while miR-
145 was also overexpressed by 2, 1.2 and 4 fold (U87,
U251 and U373 respectively) (Figure 3B). The parallel
movement in expression between these molecules across
cell lines was striking (Figure 3A vs. 3B). We also per-
formed qRT-PCR for quantitation and validation of
microarray results. As expected, the expression of these
miRNAs differed significantly between parental and IM-
3 cells: ~3 fold change of both miR-143 and -145 in
U87, ~ 2 fold change of both miR-143 and -145 in
U251, ~4 fold and ~3 fold change of miR-143 and -145
respectively in U373.
The invasion of human GBM cells was down-regulated
after treatment with antisense miR-143 and -145
To confirm the role of miR-143 and -145 in enhanced
invasiveness of IM3 cells, we tested the efficacy of com-
binatorial transfection of antisense LNA probes targeting
human miR-143 and -145 (antagoMIR® Exiqon)
Figure 1 Selection of highly invasive glioblastoma cell line subpopulations (IM3). (A) Schematic diagram of our serial selection algorithm
(Matrigel Invasion Chamber, BD Bioscience). (B) Serial selection of cells resulted in highly invasive subpopulations of each cell type. Cells (P,
parental cells) were invaded through 8 μm Matrigel® pores three times for selection of invasive cells (IM3).
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compared to untargeted/scrambled LNA probes. Dou-
ble-treatment with antisense probes against miR-143
and -145 caused a decrease in invasion within the IM3
subpopulations (Figure 4A-C). The anti-invasive effect
of these antimiRs is similar across all three human
glioma cell lines: reducing invasion counts by 40 to 50%
(Figure 4A-C). There was, however, a less predictable
effect of treatment with either antimiR-143 or -145
alone (data not shown). These results suggest that dou-
ble treatment with antimiR-143 and -145 has a synergis-
tic effect in limiting the invasion of glioblastoma cells.
Human glioblastoma expresses miR-143 and miR-145 in
typical areas of invasion
In-situ hybridization confirmed the expression of miR-
143 and miR-145 in human samples of glioblastoma. In
freshly resected tumor, the expression appears promi-
nently in the perivascular space, while tumors xeno-
grafted orthotopically into nude mice express these
molecules near the tumor-brain interface 5.
Discussion
In this study, we test the hypothesis that microRNAs are
indeed key regulators of the invasive phenotype of glio-
blastoma. We propose that two specific micro-RNAs,
miR-143 and miR-145, expressed from the same genetic
locus [9], act in concert to promote glioma invasion. In
contrast, miR-143 and miR-145 have been described by
others as a tumor suppressor molecules in most non-
neural human cancer cell lines tested [10,11]. Fewer
reports suggest a tumor type-specific difference in their
effect, and an oncogenic role in certain settings [12].
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Figure 2 Invasion, attachment, and proliferation assay of glioblastoma cells. All assays were performed with four different glioblastoma cell
lines: U87, U251, U373, and C6 (Top to bottom). Values in (A) and (B) are expressed as a percentage of corresponding parental line data. (A)
Invasion: IM-3 subpopulations were compared to their parental lines. (B) Attachment: Cells adherent to Matrigel® after 4 h were stained with
hematoxylin QS and counted. (C) Proliferation: The rate of cell proliferation was evaluated with CellTiter 96 Aqueous One Solution (Promega) at
five different time points, 4 h, 24 h, 48 h, 72 h and 96 h after seeding cells. Triangles - IM-3 lines, squares - parental. Data are represented as
means ± SD (n = 3). P, parental cells; IM3, IM3 cells; IM3, IM3 cell line; **, p < 0.01.
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Finally, Cordes et al. suggest a role for miR-143/145 in
promoting the differentiation of neural crest cells into vas-
cular smooth muscle [9]. Future investigations will help
define whether there is a causal connection between miR-
143 and miR-145 promoting invasion and decreasing
tumor growth or, alternatively, promoting more mesench-
ymal behavior.
Serial selected invasive cell line (IM3)
The process of glioblastoma invasion into surrounding
parenchyma is complex - involving cell attachment,
cytoskeletal remodeling, membrane deformation, extra-
cellular matrix proteolysis, detachment, and altered
metabolic demands [13-15]. One model for examining
the myriad of genetic and epigenetic alterations necessary
for invasion was created in our laboratory via serial selec-
tion through Matrigel® in a modified Boyden chamber
[16]. Invasion towards a serum gradient, trypsinization,
regrowth, and further iterative invasion proved to be a
reproducible method for selecting invasive glioma cells.
Further, the invasive phenotype of selected cells has
remained constant through multiple passages (up to 20)
and through freeze-thaw cycles (up to 3 tested). Even in
the C6 rat glioma cell line, the most invasive of the four
lines tested in these experiments, we were able to create
a phenotypically distinct subpopulation.
Figure 3 Expression level of miR-143 and -145 in human glioblastoma cells by miRNA probe array. The miRNA expression profile in each
of eight glioblastoma cell populations was determined by using miRCURY LNA microRNA Arrays. (A) Two way hierarchical clustering of human
glioblastma cells (U87, U251, U373) was represented by the heat map diagram. miRNA and sample clustering tree appear on the right and at
the top respectively. The color scale at the bottom demonstrates the expression level of miRNAs across all samples: red color represents the
expression level above the mean, blue color represents the expression level lower than the mean. (B) The diagram illustrates the differentially
expressed miRNAs in IM3/parental cells of three human glioblastma cell lines (U87, U251, U373). Each bar represents the fold change between
IM3 cells and Parental cells. Fold change > 1 indicates up-regulation of miRNA expression in IM3 cells while fold change < 1 indicates down-
regulation of miRNA expression in IM3. Green: U87; Red: U373; Blue: U251 (C) The expression of miRNA was quantitated and validated with qRT-
PCR analysis. All reactions were performed in triplet.
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Figure 4 Invasion assay with double antisense microRNA (DblamiR) treated IM3 cells. U87 (A), U251 (B), and U373 (C) IM-3 cells were
transfected with anti-miR-143 and anti-miR-145 (50 nM each) or with scrambled anti-miR (50 nM) as a control prior to running triplicate invasion
assays. Data are represented as mean percentage of control treated cells ± SD. P: IM3: IM3 cells. C: scramble sequence miRNA control; amiR,
antisense micro RNA; **, p < 0.01.
Figure 5 Expression of miR-143 and -145 in human glioblastoma by miRNA probe In situ hybridization. miRNA probe (FITC labeled miR-
143 or -145) staining demonstrates the expression of miR-143 (A) and -145 (B) in frozen tissue section of human glioblastoma (V: blood vessel,
patient sample) and the expression of miR-143 (C) and -145 (D) in human glioblastoma xenografted in frozen mouse brain section (T: tumor
region; B: normal brain region).
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Overexpression of miR-143 and miR-145 in glioblastoma
cells
From our collection of cell lines and their more invasive
sub-populations, we extracted RNA and generated
miRNA expression data by hybridization to a popular
microarray platform [17]. Accordingly, we were inter-
ested in miRNAs whose expression was increased in all
the invasive subpopulations compared to their parental
lines, or those miRNAs whose expression was uniformly
decreased in invasive cells. Data used to make this deci-
sion was derived from the three human glioma lines
(U87, U373, U251), all using the same human-specific
Exiqon expression array platform. Although we had no
a priori knowledge of the genetic loci involved, we
noticed a significant parallel in the pattern of upregula-
tion of miR-143 and miR-145 across the three human
lines (Figure 3B). Investigation of the chromosomal loca-
tion of these miRNAs confirmed a reasonable explana-
tion for the parallel expression - they are encoded in the
same transcript [9,18].
Expression of miR-143 and miR-145 in resected human
glioblastoma samples
Owing to its unique matrix composition, the use of
Matrigel® for selection of invasive glioma cells may bias
our results towards identification of mediators of moti-
lity along basement membranes [19]. Yet, the propensity
of glioblastoma to invade into these spaces: the perivas-
cular Virchow-Robin space and the subpial plane, has
been recognized since Scherer published landmark
papers [20]. In our hands, in situ hybridization con-
firmed the expression of miR-143 and miR-145 along
the perivascular space in frozen samples of resected
human glioblastoma (Figure 5A-D). The downstream
effects of the expressing the miR-143/-145 locus may
allow for enhanced mobility along the unique extracellu-
lar matrix outside cerebral vasculature. In xenograft
samples of glioblastoma, grown in the brains of nude
mice, we found enhanced expression of miR-143 and
miR-145 on either side of the tumor-host brain interface
(Figure 5A, B). Although a typical basement membrane
matrix has not been described at the interface between
xenograft tumor and host brain, reactive astrocytes
(fibronectin), and the invading tumor itself (vitronectin,
proteoglycans) can both secrete ECM components
shared by the Matrigel® substrate [21,22]. Our selection
of cells capable of invading through Matrigel® may have
identified those with cellular machinery allowing growth
and invasion along the Virchow-Robin space and the
brain-tumor interface. In situ regional expression of our
target microRNAs in tumor samples illustrates, once
again, the regional heterogeneity of glioblastoma, and
supports our hypothesis about their role in mediating
invasion.
Synergistic anti-invasive effect of knocking down both of
miR-143 and miR-145
In a series of transient transfection experiments, we have
shown that antisense microRNAs treatment knocking
down miR-143 and miR -145, in combination, abrogates
the invasive phenotype of each of our human glioma cell
lines (Figure 4A-C). Interestingly, in the U87 cell line,
miR-145 knockdown alone was sufficient to produce a
reduction in invasive phenotype (Data not shown), while
in other cell lines, the combined treatment was needed to
see the same effect. This finding underscores the necessity
to characterize the expression of possible downstream tar-
gets across multiple human glioblastoma lines and primary
cultures, and to find those characteristic differences
between lines that account for the inconsistencies. More
importantly, this points towards a molecular synergy that
is not yet defined.
Potential targets of miR-143/miR-145 and future
directions
In an effort to characterize the important downstream tar-
gets of miR-143 and miR-145, we utilized three algorithms
to score the likelihood of each to hybridize to, and affect
translation of, particular genes. The on-line search algo-
rithms TargetScan, PicTar, and MicroCosm were all used
to stratify targets. By filtering the resulting lists for those
targets that were identified by multiple search algorithms,
we found a number of potential miR-145 targets (espe-
cially srGAP1) in the Slit/Robo pathway, which was
recently recognized as an inhibitor of brain tumor cellular
migration and invasion [23,24]. In western-blot experi-
ments, we recognized a decreased expression of srGAP1
in the invasive subpopulation of U87 cells. Further defini-
tion of the role of srGAP1 activity, along with clearer
understanding of other downstream mediators of both
miR-143 and miR-145 is necessary.
The relationship between miR-143/miR-145 expression
and other known mediators of glioma invasion must be
defined. Very recently, Yan et al. described the likely
micro-RNA regulators of MMP-9 expression - a molecule
with known importance in survival and invasion of glio-
blastoma [25]. According to their results, 14 miRNAs
(including miR-143, miR-210 and miR-214) positively reg-
ulate the overexpression of MMP-9 in glioma cell lines we
tested (U87 and U251). Their results support our conten-
tion that miR-143 mediates invasion. Further, on review of
our expression data, we also find miR-210 and miR-214
are upregulated in our IM-3 lines compared to their par-
ental controls. Further studies are needed to identify the
correlation between the expression of microRNAs and
matrix metalloproteases in glioblastoma.
The identification of miR-143 and miR-145 as positive
regulators of glioblastoma invasion is novel. In fact, most
authors have described these molecules as tumor
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suppressors and mediators of differentiation into vascular
smooth muscle [9,12,18]. A single report supports the
role of miR-145 as an oncogene in metastatic colorectal
cancer cells [12,26]. However, hypotheses based on data
generated from malignancies outside the central nervous
system often prove unsupported in glioblastoma. The
behavior of this tumor is unique - it is markedly invasive
in the host organ yet metastases are almost non-existent.
The tumor grows quickly, but invasive cells are often
slower-growing [27]. Emerging data from our laboratory
and those of other investigators support a role for the
miR-143/145 locus in promoting glioma invasion.
Conclusions
The micro-RNA mediators of glioblastoma invasion are
incompletely defined. We present, in this publication, a
method for creating stable and invasive subcultures of
common glioma cell lines, and we use them to define
the micro-RNA regulators of invasion. Two molecules
of interest, miR-143 and miR-145, are likely key pro-
invasive mediators, and our data correlate well with
those emerging from other investigators. Understanding
the unique pathophysiology of glioblastoma invasion will
help direct future drug design and therapies aimed at
prolonging meaningful quality of life.
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